425 related articles for article (PubMed ID: 29514782)
1. The MYC oncogene is a global regulator of the immune response.
Casey SC; Baylot V; Felsher DW
Blood; 2018 May; 131(18):2007-2015. PubMed ID: 29514782
[TBL] [Abstract][Full Text] [Related]
2. MYC: Master Regulator of Immune Privilege.
Casey SC; Baylot V; Felsher DW
Trends Immunol; 2017 Apr; 38(4):298-305. PubMed ID: 28233639
[TBL] [Abstract][Full Text] [Related]
3. MYC regulates the antitumor immune response through CD47 and PD-L1.
Casey SC; Tong L; Li Y; Do R; Walz S; Fitzgerald KN; Gouw AM; Baylot V; Gütgemann I; Eilers M; Felsher DW
Science; 2016 Apr; 352(6282):227-31. PubMed ID: 26966191
[TBL] [Abstract][Full Text] [Related]
4. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
Bellovin DI; Das B; Felsher DW
Adv Exp Med Biol; 2013; 734():91-107. PubMed ID: 23143977
[TBL] [Abstract][Full Text] [Related]
5. A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity.
Lee CC; Ho KH; Huang TW; Shih CM; Hsu SY; Liu AJ; Chen KC
Life Sci; 2021 Jul; 277():119438. PubMed ID: 33798549
[TBL] [Abstract][Full Text] [Related]
6. MYC activation is a hallmark of cancer initiation and maintenance.
Gabay M; Li Y; Felsher DW
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
[TBL] [Abstract][Full Text] [Related]
7. MYC as a regulator of ribosome biogenesis and protein synthesis.
van Riggelen J; Yetil A; Felsher DW
Nat Rev Cancer; 2010 Apr; 10(4):301-9. PubMed ID: 20332779
[TBL] [Abstract][Full Text] [Related]
8. MYC, metabolism, cell growth, and tumorigenesis.
Dang CV
Cold Spring Harb Perspect Med; 2013 Aug; 3(8):. PubMed ID: 23906881
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
10. Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Xu Y; Poggio M; Jin HY; Shi Z; Forester CM; Wang Y; Stumpf CR; Xue L; Devericks E; So L; Nguyen HG; Griselin A; Gordan JD; Umetsu SE; Reich SH; Worland ST; Asthana S; Barna M; Webster KR; Cunningham JT; Ruggero D
Nat Med; 2019 Feb; 25(2):301-311. PubMed ID: 30643286
[TBL] [Abstract][Full Text] [Related]
11. Impact of MYC in regulation of tumor cell metabolism.
Wahlström T; Henriksson MA
Biochim Biophys Acta; 2015 May; 1849(5):563-9. PubMed ID: 25038584
[TBL] [Abstract][Full Text] [Related]
12. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
13. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.
Shachaf CM; Gentles AJ; Elchuri S; Sahoo D; Soen Y; Sharpe O; Perez OD; Chang M; Mitchel D; Robinson WH; Dill D; Nolan GP; Plevritis SK; Felsher DW
Cancer Res; 2008 Jul; 68(13):5132-42. PubMed ID: 18593912
[TBL] [Abstract][Full Text] [Related]
14. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
[TBL] [Abstract][Full Text] [Related]
15. Myc induced replicative stress response: How to cope with it and exploit it.
Rohban S; Campaner S
Biochim Biophys Acta; 2015 May; 1849(5):517-24. PubMed ID: 24735945
[TBL] [Abstract][Full Text] [Related]
16. The deubiquitinase USP38 promotes cell proliferation through stabilizing c-Myc.
Xu Z; Hu H; Fang D; Wang J; Zhao K
Int J Biochem Cell Biol; 2021 Aug; 137():106023. PubMed ID: 34102342
[TBL] [Abstract][Full Text] [Related]
17. The proto-oncogene c-myc and apoptosis.
Hoffman B; Liebermann DA
Oncogene; 1998 Dec; 17(25):3351-7. PubMed ID: 9916997
[TBL] [Abstract][Full Text] [Related]
18. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
19. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
20. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
Giuriato S; Ryeom S; Fan AC; Bachireddy P; Lynch RC; Rioth MJ; van Riggelen J; Kopelman AM; Passegué E; Tang F; Folkman J; Felsher DW
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16266-71. PubMed ID: 17056717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
